Original Research Article
Year: 2022 | Month: January | Volume: 12 | Issue: 1 | Pages: 130-136
DOI: https://doi.org/10.52403/ijhsr.20220119
Prognosis and Therapeutic Biomarker in the Management of Gastric Adenocarcinoma in Brazzaville
Fidele Mambouene1, Dimitry Moudiongui2, Fabien Mouamba3, Yvon Mabiala4, Etienne Mokondjimobe5, Donatien Moukassa6, Jean Bernard Nkoua Mbon7, Ange Antoine Abena8
1,2PhD Student Pending Defense in Service at the Pathological Anatomy Laboratory of the University Hospital of Brazzaville
3Pathologist and Assistant at the Faculty of Medicine Pathological Anatomy Laboratory of the University Hospital of Brazzaville
4Medical Oncologist of the University Hospital of Brazzaville
5Professor of the Doctoral School of Health and Human Biology Faculty of Health Sciences
6Anatomopathologist, Professor at the Faculty of Medicine Head of Laboratory Department for Biomedical Research and Analysis Training Faculty of Health Sciences
7Professor, Medical Oncologist of the University Hospital of Brazzaville Head of Medical Oncology
8Professor, Coordinator of the Doctoral School of Health and Human Biology Faculty of Health Sciences
Corresponding Author: Mambouene Fidele
ABSTRACT
Introduction: Gastric cancer is predominantly represented by adenocarcinoma, which is the most common histological type. The latter develops from the gastric epithelium and remains a global public health problem. The aim of the study was to assess the overexpression of the Her2 biomarker of gastric adenocarcinoma in Brazzaville.
Materials and Methods: Samples of gastric carcinomatous tissues (paraffin blocks) were analyzed by the manual immunohistochemistry technique for the evaluation of the Her2 biomarker. Samples were collected retrospectively between January 2008 and December 2018.
Results: during this period, 52 samples were analyzed. The immunohistochemistry results show that the Her2 protein positivity rate in adenocarcinoma cases was 9.6%.
Conclusion: The results obtained during this preliminary study confirm the presence of the Her2 biomarker in 9.6% of gastric adenocarcinoma cases, which is consistent with the data in the literature.
Key words: Her2, Gastric adenocarcinoma, Immunohistochemistry.